Biogen’s stock tumbles after the U.S. proposes restricting access to its Alzheimer’s disease drug
January 12, 2022 at 09:44 AM EST
Regulators have proposed limiting access to the class of Alzheimer's disease drugs that includes the company's therapy, Aduhelm.
